P
BOLT icon

Pfizer’s Bolt Biotherapeutics BOLT Stock Holding History

Pfizer’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Hold
31,305
– – 0.06% 16
2025
Q4 		$171K Hold
31,305
– – 0.07% 16
2025
Q3 		$167K Hold
31,305
– – 0.04% 19
2025
Q2 		$181K Hold
31,305
– – 0.03% 19
2025
Q1 		$250K Hold
31,305
– – 0.05% 19
2024
Q4 		$335K Buy
+31,305
New +$378K 0.01% 21

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Pfizer's BOLT Position: Q1 2026 in Review

Pfizer held its Bolt Biotherapeutics (BOLT) position steady in Q1 2026 at 31,305 shares worth $137K. The position accounts for 0.06% of the portfolio, ranked #16.

Pfizer first reported a position in BOLT in Q4 2024 and has held it in 6 quarters since. The position peaked at $335K in Q4 2024. 24 funds tracked by Wall St. Rank hold BOLT as of Q1 2026.

  • Pfizer held 31,305 shares of Bolt Biotherapeutics worth $137K as of Q1 2026.
  • Pfizer left its Bolt Biotherapeutics share count unchanged in Q1 2026.
  • Bolt Biotherapeutics made up 0.06% of Pfizer's portfolio in Q1 2026, its #16 holding.
  • Pfizer first reported a position in Bolt Biotherapeutics in Q4 2024 and has held it in 6 quarters since.
  • Pfizer's Bolt Biotherapeutics position peaked at $335K in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2026.

Based on Pfizer's 13F filing for Q1 2026, filed 12 May 2026.